TAK — TAKEDA PHARMACEUTICAL CO LTD
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1395064 ·
Last close
$15.84
Market Cap
$50.05B
52W High
$18.90
52W Low
$14.84
ADV30
3,170,109
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,094,541,000,000 | 688,837,000,000 | 42,068,000,000 | -368,471,000,000 | 15,511,506,000,000 | 595,054,000,000 | 8,080,857,000,000 |
| Dec 2025 | 1,191,698,000,000 | 790,550,000,000 | 168,822,000,000 | 103,640,000,000 | 15,408,774,000,000 | 654,937,000,000 | 7,764,684,000,000 |
| Sep 2025 | 1,112,796,000,000 | 732,735,000,000 | 68,996,000,000 | -11,802,000,000 | 14,470,300,000,000 | 681,486,000,000 | 7,338,611,000,000 |
| Jun 2025 | 1,106,685,000,000 | 722,010,000,000 | 184,565,000,000 | 124,243,000,000 | 14,004,537,000,000 | 350,008,000,000 | 7,138,357,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,189,062,000,000
Investing CF
$-330,806,000,000
Financing CF
$-721,117,000,000
CapEx
$-442,990,000,000
Dividends Paid
$-312,852,000,000
Buybacks
$-101,581,000,000
EPS Diluted TTM
$39.12
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$1,095,662,000,000
Inventory
$1,407,192,000,000
Receivables
$757,921,000,000
ST Investments
$107,004,000,000
EBIT TTM
$496,862,000,000
Pretax Income TTM
$205,369,000,000
Interest Exp TTM
$291,493,000,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,505,720,061,952
EBITDA
$1,236,273,987,584
Free Cash Flow
$672,782,745,600
Enterprise Value
$4,932,561,272,832
Total Cash
$595,053,969,408
Total Debt
$5,476,358,029,312
Shares Out
3,159,748,660
Trailing EPS
$-0.30
Book Value
$14.57
ROE
-2.1%
ROA
2.6%
Div Yield
4.17%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 4,505,720,000,000 | 464,451,000,000 | -152,390,000,000 | 15,511,506,000,000 | 8,080,857,000,000 | — | 1,041,431,000,000 |
| Mar 2025 | 4,581,551,000,000 | 486,061,000,000 | 107,928,000,000 | 14,248,344,000,000 | 7,312,365,000,000 | — | 1,057,182,000,000 |
| Mar 2024 | 4,263,762,000,000 | 366,165,000,000 | 144,067,000,000 | 15,108,792,000,000 | 7,834,787,000,000 | — | 716,344,000,000 |
| Mar 2023 | 4,027,478,000,000 | 587,812,000,000 | 317,017,000,000 | 13,957,750,000,000 | 7,603,079,000,000 | — | 977,156,000,000 |
| Mar 2022 | 3,569,006,000,000 | 546,043,000,000 | 230,059,000,000 | 13,178,018,000,000 | 7,494,495,000,000 | — | 1,123,105,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.53
Max Pain — expiry 2026-07-17
max pain strike: $15.00 · spot: $15.85 · call oi: 1,680 · put oi: 2,679
Expected Move to 2026-07-17:
±$1.07
(6.78%) —
implied range
$14.77 –
$16.92
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TKPHF | TAKEDA PHARMACEUTICAL CO LTD | $47.70B | $30.19 | — |
| REGN | REGENERON PHARMACEUTICALS, INC. | $63.67B | $618.03 | — |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $38.67B | $33.21 | — |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.48B | $288.18 | — |
| TEVJF | TEVA PHARMACEUTICAL INDUSTRIES LTD | $35.33B | $30.34 | — |
News headlines (Yahoo Finance, 1h cache)
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
2026-06-24 07:05 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
2026-06-23 14:48 · Yahoo
Takeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
2026-06-23 12:00 · Yahoo
Denali to Sell Priority Review Voucher for $195M Cash Boost
2026-06-19 12:40 · Yahoo
Boltz Announces Collaboration with Takeda to Deploy Frontier Biomolecular AI Models Across Takeda's Research Organization
2026-06-18 14:03 · Yahoo
Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight
2026-06-18 14:01 · Yahoo
Takeda (TSE:4502) Unveils Phase 3 Wins In Narcolepsy And Psoriasis
2026-06-16 18:13 · Yahoo
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
2026-06-15 16:00 · Yahoo
AI-Driven Bispecific Antibody Development Attracts $1+ Billion in Pharma Investments Amid Clinical Risk Mitigation Focus
2026-06-15 14:54 · Yahoo
Takeda Designed A Psoriasis Pill Using AI. It Just Walloped Bristol's Sotyktu In A Head-To-Head Test.
2026-06-11 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.